Neutrophil counts and the risk of new-onset proteinuria in hypertensive patients

Supplemental Material

Figure S1. Flow chart of the participants

Table S1. Characteristics of the included and excluded participants

Table S2. Characteristics of study participants by quintiles of neutrophil counts in the

 enalapril only group

Table S3. The relationship of white blood cell (WBC) counts with new-onset proteinuria in the enalapril only group

Table S4. The relationship of neutrophil counts with new-onset proteinuria in the

 enalapril only group with further adjustment for lymphocyte counts

Table S5. Concomitant medication usage during the treatment period by quintiles of

 neutrophil counts in the enalapril only group

Table S6. The relationship of neutrophil counts with new-onset proteinuria in the enalapril only group with further adjustment for calcium channel blocker usage during the treatment period

Table S7. Effect modification of neutrophil counts on efficacy of folic acid in

 prevention of new-onset proteinuria with further adjustment for lymphocyte counts

Table S8. Effect modification of neutrophil counts on efficacy of folic acid in prevention of new-onset proteinuria with further adjustment for calcium channel blocker usage during the treatment period

Table S9. Effect modification of neutrophil counts on efficacy of folic acid in prevention of new-onset proteinuria with further adjustment for annual rate of eGFR decline during the treatment period

1




Figure S1. Flow chart of the participants

Variables	Excluded	Included
N	5990	9114
Age, year	59.4 ± 7.8	59.5 ± 7.4
Male, No. (%)	2441 (40.8)	3461 (38.0)
Body mass index, kg/m ²	25.6 ± 3.6	25.7 ± 3.6
Current smoking, No. (%)	1512 (25.3)	1905 (20.9)
Blood pressure, mmHg		
Baseline SBP	168.9 ± 20.9	167.9 ± 21.0
Baseline DBP	95.9 ± 12.1	95.0 ± 11.8
Time-averaged SBP	140.4 ± 11.7	139.6 ± 11.0
Time-averaged DBP	84.1 ± 7.7	83.6 ± 7.3
Laboratory results		
Total cholesterol, mmol/L	5.9 ± 1.2	5.6 ± 1.2
Triglycerides, mmol/L	1.7 ± 0.9	1.7 ± 1.4
HDL-C, mmol/L	1.4 ± 0.4	1.3 ± 0.4
Fasting glucose, mmol/L	6.1 ± 1.9	6.0 ± 1.7
Uric acid, µmol/L	294.5 ± 79.0	294.0 ± 79.4
eGFR, mL/min/1.73m ²	93.6 ± 12.8	94.5 ± 12.8
Folate, ng/mL	7.5 ± 3.1	7.8 ± 3.3
Total homocysteine, µmol/L	14.9 ± 9.5	14.5 ± 8.7
White blood cell counts, 109/L	6.6 ± 2.0	6.6 ± 1.9
Neutrophil counts, 10 ⁹ /L	4.0 ± 1.5	3.9 ± 1.6
Lymphocyte counts, 10 ⁹ /L	2.1 ± 0.7	2.1 ± 0.7
Medication use, No. (%)		
Antihypertensive drugs	2854 (47.6)	4601 (50.5)
Glucose-lowering drugs	114 (1.9)	161 (1.8)
Lipid-lowering drugs	52 (0.9)	76 (0.8)
Antiplatelet drugs	268 (4.5)	317 (3.5)

Table S1. Characteristics of the included and excluded participants

*Variables are presented as Mean \pm SD or n (%)

Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL-C, high density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate.

Variablas	Neutrophil counts, 10 ⁹ /L					
Variables	Q1(<2.7)	Q2(2.7-<3.3)	Q3(3.3-<4.0)	Q4(4.0-<4.8)	Q5(≥4.8)	P value
Ν	700	799	911	804	893	
Age, year	58.3 ± 7.1	59.1 ± 7.5	59.4 ± 7.4	60.2 ± 7.4	60.0 ± 7.7	< 0.001
Male, No. (%)	212 (30.3)	280 (35.0)	361 (39.6)	355 (44.2)	346 (38.7)	< 0.001
Body mass index, kg/m ²	25.3 ± 3.5	25.7 ± 3.4	25.9 ± 3.5	25.7 ± 3.6	25.4 ± 3.7	0.016
Current smoking, No. (%)	108 (15.4)	139 (17.4)	195 (21.4)	205 (25.5)	228 (25.5)	< 0.001
Blood pressure, mmHg						
Baseline SBP	165.4 ± 19.8	167.0 ± 20.0	167.8 ± 20.8	168.0 ± 20.3	168.4 ± 21.0	0.038
Baseline DBP	94.1 ± 11.0	94.2 ± 11.5	95.1 ± 12.1	94.9 ± 11.5	94.9 ± 12.2	0.264
Time-averaged SBP	137.9 ± 10.5	139.3 ± 10.9	139.5 ± 10.6	139.4 ± 11.2	140.2 ± 10.8	0.001
Time-averaged DBP	83.6 ± 6.8	83.4 ± 7.5	83.7 ± 7.2	83.4 ± 7.3	83.3 ± 7.4	0.718
Laboratory results						
Total cholesterol, mmol/L	5.5 ± 1.1	5.6 ± 1.2	5.6 ± 1.1	5.6 ± 1.1	5.7 ± 1.3	0.005
Triglycerides, mmol/L	1.5 ± 0.7	1.7 ± 0.9	1.7 ± 1.1	1.7 ± 0.9	1.8 ± 1.0	< 0.001
HDL-C, mmol/L	1.4 ± 0.4	1.3 ± 0.4	1.3 ± 0.4	1.3 ± 0.4	1.3 ± 0.4	0.085
Fasting glucose, mmol/L	5.9 ± 1.3	6.1 ± 1.7	5.9 ± 1.6	6.0 ± 1.6	6.1 ± 1.8	0.045
Uric acid, µmol/L	276.6 ± 74.9	288.5 ± 74.4	299.1 ± 80.1	299.2 ± 84.0	293 ± 76.4	< 0.001
eGFR, mL/min/1.73m ²	96.5 ± 10.6	95.6 ± 11.7	95.0 ± 12.1	94.0 ± 12.0	94.6 ± 12.3	< 0.001
Folate, ng/mL	8.2 ± 3.4	7.8 ± 3.0	7.9 ± 3.0	7.8 ± 3.8	7.6 ± 3.5	0.009
Total homocysteine, µmol/L	13.6 ± 8.6	14.3 ± 8.3	13.9 ± 7.7	14.5 ± 7.8	15.2 ± 9.6	0.002
WBC counts, 10 ⁹ /L	4.5 ± 0.8	5.5 ± 0.7	6.3 ± 0.7	7.1 ± 0.9	8.9 ± 1.8	< 0.001
Neutrophil counts, 109/L	2.2 ± 0.3	3 ± 0.2	3.6 ± 0.2	4.3 ± 0.2	6.0 ± 2.4	< 0.001
Lymphocyte counts, 109/L	1.8 ± 0.6	2.0 ± 0.6	2.1 ± 0.6	2.2 ± 0.7	2.3 ± 1.2	< 0.001
Medication use, No. (%)						
Antihypertensive drugs	344 (49.1)	406 (50.8)	467 (51.3)	393 (48.9)	449 (50.3)	0.844
Glucose-lowering drugs	1 (0.1)	10 (1.3)	22 (2.4)	12 (1.5)	16 (1.8)	0.005
Lipid-lowering drugs	5 (0.7)	4 (0.5)	7 (0.8)	10 (1.2)	10(1.1)	0.479
Antiplatelet drugs	20 (2.9)	35 (4.4)	36 (4.0)	29 (3.6)	29 (3.2)	0.537

Table S2. Characteristics of study participants by quintiles of neutrophil counts in the enalapril only group.

*Variables are presented as Mean \pm SD or n (%)

Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL-C, high density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; WBC, white blood cell.

WDC		Crude model	Adjusted model*
WBC counts, 10 ⁹ /L	Events /N (%)	OR (95% CI)	OR (95% CI)
Quintiles			
Q1 (<5.1)	26/800(3.3)	Ref	Ref
Q2 (5.1-<5.9)	32/779(4.1)	1.28(0.75, 2.16)	1.23(0.72, 2.09)
Q3 (5.9-<6.7)	25/803(3.1)	0.96(0.55, 1.67)	0.84(0.48, 1.49)
Q4 (6.7-<7.8)	38/870(4.4)	1.36(0.82, 2.26)	1.20(0.71, 2.01)
Q5 (≥7.8)	39/855(4.6)	1.42(0.86, 2.36)	1.27(0.75, 2.13)
Categories			
Q1 (<5.1)	26/800(3.3)	Ref	Ref
Q2-4 (5.1-<7.8)	95/2452(3.9)	1.20(0.77, 1.87)	1.09(0.69, 1.70)
Q5 (≥7.8)	39/855(4.6)	1.42(0.86, 2.36)	1.27(0.75, 2.13)
Categories			
Q1-4(<7.8)	121/3252(3.7)	Ref	Ref
Q5 (≥7.8)	39/855(4.6)	1.24(0.86, 1.79)	1.18(0.81, 1.74)

Table S3. The relationship of white blood cell (WBC) counts with new-onset proteinuria in the enalapril only group.

*Adjusted for age, sex, body mass index, smoking status, fasting glucose, total cholesterol, triglycerides, high density lipoprotein cholesterol, estimated glomerular filtration rate, uric acid, folate, total homocysteine, *MTHFR* C677T genotypes, systolic blood pressure (SBP) at baseline, as well as time-averaged SBP during the treatment period.

NT (111 (109/T		Crude model	Adjusted model*
Neutrophil counts, 10 ⁹ /L	Events /N (%) OR (95% CI)		OR (95% CI)
Categories			
Q1 (<2.7)	18/700(2.6)	Ref	Ref
Q2-4 (2.7-<4.8)	96/2514(3.8)	1.50(0.90, 2.51)	1.34(0.80, 2.26)
Q5 (≥4.8)	46/893(5.2)	2.06(1.18, 3.58)	1.87(1.05, 3.33)
Categories			
Q1-4 (<4.8)	114/3214(3.5)	Ref	Ref
Q5 (≥4.8)	46/893(5.2)	1.48(1.04, 2.10)	1.47(1.02, 2.11)

Table S4. The relationship of neutrophil counts with new-onset proteinuria in the enalapril only group with further adjustment for lymphocyte counts.

*Adjusted for age, sex, body mass index, smoking status, fasting glucose, total cholesterol, triglycerides, high density lipoprotein cholesterol, estimated glomerular filtration rate, uric acid, folate, total homocysteine, *MTHFR* C677T genotypes, lymphocyte counts, systolic blood pressure (SBP) at baseline, as well as time-averaged SBP during the treatment period.

Medication, No. (%)	Neutrophil counts, 10 ⁹ /L					Р
Medication, No. (70)	Q1(<2.7)	Q2(2.7-<3.3)	Q3(3.3-<4.0)	Q4(4.0-<4.8)	Q5(≥4.8)	value
Anti-hypertension drugs						
Calcium channel blockers	542 (77.4)	666 (83.4)	759 (83.3)	646 (80.3)	720 (80.6)	0.016
Diuretics	413 (59.0)	499 (62.5)	556 (61.0)	487 (60.6)	556 (62.3)	0.642
Glucose-lowering drugs	8 (1.1)	13 (1.6)	15 (1.6)	11 (1.4)	17 (1.9)	0.783
Lipid-lowering drugs	0 (0.0)	1 (0.1)	0 (0.0)	0 (0.0)	2 (0.2)	0.303
Antiplatelet drugs	1 (0.1)	8 (1.0)	7 (0.8)	8 (1.0)	9 (1.0)	0.279

Table S5. Concomitant medication usage during the treatment period by quintiles of neutrophil counts in the enalapril only group.

*Regular concomitant medication use was defined as 180 or more cumulative days of taking the drug of interest.

Table S6. The relationship of neutrophil counts with new-onset proteinuria in the enalapril only group with further adjustment for calcium channel blocker usage during the treatment period.

NT (1.11 (109/T		Crude model	Adjusted model*
Neutrophil counts, 10 ⁹ /L	Events /N (%)	OR (95% CI)	OR (95% CI)
Categories			
Q1 (<2.7)	18/700(2.6)	Ref	Ref
Q2-4 (2.7-<4.8)	96/2514(3.8)	1.50(0.90, 2.51)	1.31(0.78, 2.20)
Q5 (≥4.8)	46/893(5.2)	2.06(1.18, 3.58)	1.79(1.02, 3.15)
Categories			
Q1-4 (<4.8)	114/3214(3.5)	Ref	Ref
Q5 (≥4.8)	46/893(5.2)	1.48(1.04, 2.10)	1.43(1.00, 2.06)

*Adjusted for age, sex, body mass index, smoking status, fasting glucose, total cholesterol, triglycerides, high density lipoprotein cholesterol, estimated glomerular filtration rate, uric acid, folate, total homocysteine, *MTHFR* C677T genotypes, systolic blood pressure (SBP) at baseline, as well as time-averaged SBP and calcium channel blocker usage during the treatment period.

Table S7. Effect modification of neutrophil counts on efficacy of folic acid in
prevention of new-onset proteinuria with further adjustment for lymphocyte
counts.

Neutrophil counts,	Enalapril	Enalapril–Fo lic Acid	Crude model		Adjusted model*	
10 ⁹ /L	Events/	Events/	OR (95% CI)	<i>P</i> for	OR (95% CI)	P for
	N (%)	N (%)	OK (5576 CI)	Interaction	OK (5576 CI)	Interaction
<4.8	114/3214(3.5)	109/3245(3.4)	0.95(0.72, 1.23)	0.044	0.93(0.71, 1.22)	0.035
≥4.8	46/893(5.2)	24/856(2.8)	0.53(0.32, 0.88)		0.49(0.29, 0.82)	

*Adjusted for age, sex, body mass index, smoking status, fasting glucose, total cholesterol, triglycerides, high density lipoprotein cholesterol, estimated glomerular filtration rate, uric acid, folate, total homocysteine, *MTHFR* C677T genotypes, lymphocyte counts, systolic blood pressure (SBP) at baseline, as well as time-averaged SBP during the treatment period.

Table S8. Effect modification of neutrophil counts on efficacy of folic acid in prevention of new-onset proteinuria with further adjustment for calcium channel blocker usage during the treatment period.

Neutrophil counts,	Enalapril	Enalapril–Fo lic Acid	Crude model	Adjusted model		
10 ⁹ /L	Events/	Events/	OR (95% CI)	<i>P</i> for	OR (95% CI)	P for
	N (%)	N (%)	OK ()5/0 CI)	Interaction	OK ()5/0 CI)	Interaction
<4.8	114/3214(3.5)	109/3245(3.4)	0.95(0.72, 1.23)	0.044	0.93(0.71, 1.22)	0.036
≥4.8	46/893(5.2)	24/856(2.8)	0.53(0.32, 0.88)		0.49(0.29, 0.83)	

*Adjusted for age, sex, body mass index, smoking status, fasting glucose, total cholesterol, triglycerides, high density lipoprotein cholesterol, estimated glomerular filtration rate, uric acid, folate, total homocysteine, *MTHFR* C677T genotypes, systolic blood pressure (SBP) at baseline, as well as time-averaged SBP and calcium channel blocker usage during the treatment period.

Table S9. Effect modification of neutrophil counts on efficacy of folic acid in
prevention of new-onset proteinuria with further adjustment for annual rate of
eGFR decline during the treatment period.

Neutrophil counts,	Enalapril	Enalapril–Fo lic Acid	Crude model		Adjusted model	
10 ⁹ /L	Events/	Events/	OR (95% CI)	<i>P</i> for	OR (95% CI)	<i>P</i> for
	N (%)	N (%)	OK ()5/0 CI)	Interaction	OK (5570 CI)	Interaction
<4.8	114/3214(3.5)	109/3245(3.4)	0.95(0.72, 1.23)	0.044	0.94(0.71, 1.24)	0.040
≥4.8	46/893(5.2)	24/856(2.8)	0.53(0.32, 0.88)		0.49(0.29, 0.83)	

*Adjusted for age, sex, body mass index, smoking status, fasting glucose, total cholesterol, triglycerides, high density lipoprotein cholesterol, estimated glomerular filtration rate (eGFR), uric acid, folate, total homocysteine, *MTHFR* C677T genotypes, systolic blood pressure (SBP) at baseline, as well as time-averaged SBP and annual rate of eGFR decline during the treatment period.

Annual rate of eGFR decline, estimated as

$$1-t\sqrt{\frac{\text{eGFR at exit}}{\text{eGFR at baseline}}} \times 100\%$$
, t is the time

length in years from baseline to the exit visit.